Filter Results


Study status

(for at least one location)



Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 24 for

Edit search filters
  1. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

    Scottsdale/Phoenix, AZ

  2. A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

    Scottsdale/Phoenix, AZ

  3. A Study for the Use of Hepatitis C Virus Seropositive Donors into Hepatitis C Seronegative Liver Transplant Recipients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Sofosbuvir/GS-5816 Fixed-Dose Combination in Adults with Chronic HCV Infection and Child-Pugh Class B Cirrhosis

    Scottsdale/Phoenix, AZ

  5. A Study to Evaluate Preemptive Therapy in Hepatitis C Organ Transplant Recipients

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

    Scottsdale/Phoenix, AZ

  7. A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study to Compare the Effectiveness and Safety of ABT-493/ABT-530 to Sofosbuvir Given Together with Declatasvir in Adults with a Chronic Hepatitis C Virus Infection

    Scottsdale/Phoenix, AZ

  9. A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

    Scottsdale/Phoenix, AZ

  10. An Expanded Access Study of Sofosbuvir Combined with Ribavirin and Either with or without Pegylated Interferon for Treating Aggressive Post-Transplant Hepatitis C

    Jacksonville, FL


Mayo Clinic Footer